St. Louis-based Mallinckrodt announced that the FDA has granted priority review to its new pain drug MNK-795.
MNK-795 is a controlled-release oral formulation of oxycodone and acetaminophen that has been studied for the management of moderate to severe acute pain.
The FDA grants priority review to drugs that offer significant improvements in the safety or effectiveness of a treatment when compared to standard applications.
More Articles on Pain Management:
Study: Prescription Painkiller Overdose Deaths in Women Spike 400% in 10 YearsDr. Walter Schuyler Joins Pain Specialists of Charleston
Sibley Medical Center to Open Pain Management Clinic, Adds Dr. J. Richard Waggoner